|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ASGR1 |
Gene summary for ASGR1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ASGR1 | Gene ID | 432 |
| Gene name | asialoglycoprotein receptor 1 | |
| Gene Alias | ASGPR | |
| Cytomap | 17p13.1 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | P07306 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 432 | ASGR1 | NAFLD1 | Human | Liver | NAFLD | 2.48e-15 | 9.60e-01 | -0.04 |
| 432 | ASGR1 | S41 | Human | Liver | Cirrhotic | 1.67e-04 | 2.89e-01 | -0.0343 |
| 432 | ASGR1 | S43 | Human | Liver | Cirrhotic | 1.83e-06 | -2.46e-01 | -0.0187 |
| 432 | ASGR1 | HCC1_Meng | Human | Liver | HCC | 3.85e-87 | 7.36e-01 | 0.0246 |
| 432 | ASGR1 | HCC2_Meng | Human | Liver | HCC | 1.89e-12 | -3.95e-01 | 0.0107 |
| 432 | ASGR1 | HCC1 | Human | Liver | HCC | 2.42e-10 | 3.45e+00 | 0.5336 |
| 432 | ASGR1 | HCC2 | Human | Liver | HCC | 2.67e-07 | 2.56e+00 | 0.5341 |
| 432 | ASGR1 | Pt13.a | Human | Liver | HCC | 8.00e-05 | -9.97e-02 | 0.021 |
| 432 | ASGR1 | Pt13.b | Human | Liver | HCC | 4.14e-32 | 1.67e-03 | 0.0251 |
| 432 | ASGR1 | Pt14.a | Human | Liver | HCC | 2.09e-11 | 8.83e-01 | 0.0169 |
| 432 | ASGR1 | Pt14.b | Human | Liver | HCC | 1.94e-13 | 4.90e-01 | 0.018 |
| 432 | ASGR1 | Pt14.d | Human | Liver | HCC | 1.10e-02 | 1.79e-01 | 0.0143 |
| 432 | ASGR1 | S014 | Human | Liver | HCC | 8.25e-25 | 1.59e+00 | 0.2254 |
| 432 | ASGR1 | S015 | Human | Liver | HCC | 1.73e-26 | 1.90e+00 | 0.2375 |
| 432 | ASGR1 | S016 | Human | Liver | HCC | 4.32e-29 | 1.40e+00 | 0.2243 |
| 432 | ASGR1 | S027 | Human | Liver | HCC | 5.73e-05 | 1.04e+00 | 0.2446 |
| 432 | ASGR1 | S028 | Human | Liver | HCC | 4.88e-29 | 1.67e+00 | 0.2503 |
| 432 | ASGR1 | S029 | Human | Liver | HCC | 7.12e-27 | 2.06e+00 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00068984 | Liver | NAFLD | receptor-mediated endocytosis | 49/1882 | 244/18723 | 1.80e-06 | 7.78e-05 | 49 |
| GO:00714967 | Liver | NAFLD | cellular response to external stimulus | 51/1882 | 320/18723 | 6.21e-04 | 8.18e-03 | 51 |
| GO:007149612 | Liver | Cirrhotic | cellular response to external stimulus | 123/4634 | 320/18723 | 3.27e-08 | 1.10e-06 | 123 |
| GO:00316686 | Liver | Cirrhotic | cellular response to extracellular stimulus | 96/4634 | 246/18723 | 4.55e-07 | 1.05e-05 | 96 |
| GO:000689811 | Liver | Cirrhotic | receptor-mediated endocytosis | 91/4634 | 244/18723 | 8.13e-06 | 1.22e-04 | 91 |
| GO:007149622 | Liver | HCC | cellular response to external stimulus | 191/7958 | 320/18723 | 3.40e-10 | 1.13e-08 | 191 |
| GO:003166812 | Liver | HCC | cellular response to extracellular stimulus | 149/7958 | 246/18723 | 7.35e-09 | 1.86e-07 | 149 |
| GO:000689821 | Liver | HCC | receptor-mediated endocytosis | 134/7958 | 244/18723 | 5.73e-05 | 5.31e-04 | 134 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ASGR1 | SNV | Missense_Mutation | c.695N>T | p.Gly232Val | p.G232V | P07306 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-FU-A2QG-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ASGR1 | SNV | Missense_Mutation | novel | c.163N>T | p.Val55Phe | p.V55F | P07306 | protein_coding | deleterious(0.03) | possibly_damaging(0.549) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ASGR1 | SNV | Missense_Mutation | novel | c.676N>A | p.Gly226Arg | p.G226R | P07306 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| ASGR1 | SNV | Missense_Mutation | novel | c.532N>A | p.Ala178Thr | p.A178T | P07306 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| ASGR1 | SNV | Missense_Mutation | c.742N>A | p.Gly248Arg | p.G248R | P07306 | protein_coding | tolerated(0.16) | probably_damaging(0.988) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ASGR1 | SNV | Missense_Mutation | novel | c.778G>A | p.Asp260Asn | p.D260N | P07306 | protein_coding | tolerated(0.34) | benign(0.001) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| ASGR1 | SNV | Missense_Mutation | novel | c.832N>A | p.Glu278Lys | p.E278K | P07306 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B5-A11Y-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| ASGR1 | SNV | Missense_Mutation | c.633N>T | p.Trp211Cys | p.W211C | P07306 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| ASGR1 | SNV | Missense_Mutation | novel | c.727N>A | p.Asp243Asn | p.D243N | P07306 | protein_coding | tolerated(0.64) | benign(0.059) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| ASGR1 | SNV | Missense_Mutation | novel | c.342N>T | p.Lys114Asn | p.K114N | P07306 | protein_coding | deleterious(0) | benign(0.079) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 432 | ASGR1 | EXTERNAL SIDE OF PLASMA MEMBRANE, DRUGGABLE GENOME | AMG 529 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |